Navigation Links
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/13/2013

00 p.m. Pacific Time with management to discuss results from the meeting as well as financial results for the first quarter and provide a general corporate update.

About Anthera PharmaceuticalsAnthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.  Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
2. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
3. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
6. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
7. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
8. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
9. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
11. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Una presentazione speciale durante la settimana ... esperti di MERG valutare i successi ottenuti ... di svariate popolazioni di pazienti affetti dalla patologia. ... Ronnie Fass , MD della Case Western Reserve ... clinici relativi alla terapia Stretta. Un panel di esperti ...
(Date:5/27/2015)... Biosensors International Group, Ltd. ("Biosensors " or the "Company", ... manufacturer and marketer of innovative medical devices, today announced ... and fiscal full year ended 31 March 2015 ("FY15"). ... , Q4 FY15: , Total revenue of US$75.9 ... Year 2014 ("Q4 FY14") due to licensing revenue reduction ...
(Date:5/27/2015)... , May 27, 2015  PDL BioPharma, Inc. (PDL) ... P. McLaughlin , the company,s president and chief executive ... Conference next week in New York City.  The presentation, ... 3, 2015 at 11:30 a.m. EDT. To ... presentation, go to the Company,s website at http://www.pdl.com ...
Breaking Medicine Technology:Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 2Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 3Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 4Biosensors Reports Financial Results for Fiscal Year 2015 2Biosensors Reports Financial Results for Fiscal Year 2015 3Biosensors Reports Financial Results for Fiscal Year 2015 4Biosensors Reports Financial Results for Fiscal Year 2015 5Biosensors Reports Financial Results for Fiscal Year 2015 6Biosensors Reports Financial Results for Fiscal Year 2015 7PDL BioPharma to Present at Jefferies 2015 Global Healthcare Conference 2
... Encouraging 12-Month Outcomes from, Single- Center Study Involving ... 14 OrbusNeich today announced that an,interim analysis ... show good safety and efficacy in the real-world ... Presented by Professor Robbert de Winter, M.D., Ph.D., ...
... study Study needed ... Oct. 13 Advanced Circulatory Systems, Inc.,( http://www.advancedcirculatory.com ) ... in funding from the National Institutes of,Health (NIH) to ... on,those who experience cardiac arrest outside a hospital. Whatcom ...
Cached Medicine Technology:Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2
(Date:5/27/2015)... The news is full of companies getting ... documentation or appropriate training: an automobile manufacturer, a store ... company in Texas and the list goes on. The ... due to improper training and documentation (Osha.gov). eLeaP ... the new Supervisor feature which provides a powerful tool ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Danish scientists ... line” biomarkers that have the potential to help in ... to read the full story that has just ... University in Aalborg, Denmark say new biomarkers found in ... outlook for patients with malignant mesothelioma . ...
(Date:5/27/2015)... The Society for Women's Health Research ... research on sex differences in health and disease, today ... advocates, organizations, and celebrities in bringing awareness to the ... campaign features a short film that shares the stories ... as a result of their abuse, as well as ...
(Date:5/27/2015)... May 27, 2015 National ... partner, award winning web development and interactive ... announce the launch of its newly redesigned, ... , National Healthcare Providers, is a physician ... in the areas of Radiology, Anesthesiology, Emergency ...
(Date:5/27/2015)... silver spring, MD (PRWEB) May 27, 2015 ... Company in USA, helped its client to launch an ... Payment app allows merchants to accept credit, debit and ... be downloaded from Google Play at: https://play.google.com/store/apps/details?id=com.simpalm.paymentgateway . ... Jan 2013 and has been recently updated by SIMpalm. ...
Breaking Medicine News(10 mins):Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 3Health News:New Report Highlights Current and Emerging Biomarkers for Mesothelioma, According to Surviving Mesothelioma 2Health News:The Society for Women’s Health Research Announces “Beyond the Bruises” Campaign Highlighting the Effects of Domestic Violence on Chronic Disease 2Health News:The Society for Women’s Health Research Announces “Beyond the Bruises” Campaign Highlighting the Effects of Domestic Violence on Chronic Disease 3Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 2Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 3Health News:Forte Payment System Launches Android Version of Payment App 2
... CARLSBAD, Calif., Oct. 2 Isis,Pharmaceuticals, Inc. (Nasdaq: ... received,clearance under the Hart-Scott-Rodino Antitrust Improvements Act for ... company, which,was announced on September 13, 2007. ... to Ortho-McNeil,worldwide development and commercialization rights to two ...
... for a loved one with dementia, TUCSON, Ariz., ... a new book that aims to ease the challenges ... and,Families are Still Asking WHY?, author Jim Greenwood, whose ... and useful,advice on how to best care for a ...
... Recruitment Efforts for Pulmonary Study, SOLANA ... Solutions, LLC, a firm specializing in patient ... its team of Regional Recruitment,Specialists(TM) in support ... of,Chronic Obstructive Pulmonary Disease (COPD) for a ...
... for Massachusetts Firms, WASHINGTON, Oct. 1 ... bill with provisions secured by,Senator John Kerry (D-Mass.) ... through 2010 and to increase the transition and,commercialization ... will ensure that the thousands of firms that ...
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) announced ... (FDA) has approved the SymlinPen(TM) 120 and ... acetate) injection. These new pre-filled pen-injector devices,feature ... control. "SymlinPen 120 and SymlinPen 60 ...
... any period of time after leaving the foster care ... than those with stable housing situations, according to a ... & Adolescent Medicine, one of the JAMA/Archives journals. Youth ... after leaving the foster care system appear to have ...
Cached Medicine News:Health News:Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc. 2Health News:Alzheimer's Caregivers Get Sage Advice 2Health News:RESolutions Rapid Enrollment Solutions, LLC Mobilizes Team of Regional Recruitment Specialists(TM) 2Health News:Kerry Extends, Improves Small Business Innovation Program 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 3Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 4Health News:Poor health care access common among youth leaving foster system 2Health News:Poor health care access common among youth leaving foster system 3
... Sysmex UF-50 is designed to bring efficiency ... It combines the superior technology of ... sample analysis. Continuous sampling or batch ... autosamplers, streamlining sample processing in high volume ...
... The iQ200 System incorporates the ... and the AUTION MAX™ AX-4280 Automated ... a fully integrated chemical and microscopic ... (APR™), a well trained neural network, ...
... The Sysmex UF-100 is designed to bring ... analysis. It combines the superior technology ... urine sample analysis. Continuous sampling or ... rack-based autosamplers, streamlining sample processing in high ...
... easy to use Ambulatory Urodynamic recorder which ... practising urologists as an invaluable aid in ... The system offers the possibility to measure ... natural bladder filling, extented over a longer ...
Medicine Products: